Everest Medicines Announces Approval of ‘B’ Marker Removal from Company’s Stock Code by the Hong Kong Stock Exchange
SHANGHAI, Apr 22, 2025 – (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) has approved the Company’s application to remove the “B” marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. “We are very pleased that Everest Medicines has satisfied the market capitalization/revenue test under Rule 8.05(3) of the Listing Rules and successfully removed the ‘B’ marker – a significant milestone for the Company in the capital markets that could lead to wider investor participation.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Moving forward, we will continue to deepen our ‘dual-engine strategy’, enhancing our commercial excellence and advance our first-i…